Citation Impact
Citing Papers
2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines
2016 Standout
Cardioprotection and Safety of Dexrazoxane in Patients Treated for Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or Advanced-Stage Lymphoblastic Non-Hodgkin Lymphoma: A Report of the Children’s Oncology Group Randomized Trial Pediatric Oncology Group 9404
2015
Changes in Cardiac Biomarkers During Doxorubicin Treatment of Pediatric Patients With High-Risk Acute Lymphoblastic Leukemia: Associations With Long-Term Echocardiographic Outcomes
2012
Therapy-Related Cardiac Risk in Childhood Cancer Survivors: An Analysis of the Childhood Cancer Survivor Study
2019
Oncogenic activation of the Notch1 gene by deletion of its promoter in Ikaros-deficient T-ALL
2010 StandoutNobel
Nox2 NADPH Oxidase Promotes Pathologic Cardiac Remodeling Associated with Doxorubicin Chemotherapy
2010
Cancer statistics, 2022
2022 Standout
Reactive Oxygen Species in Inflammation and Tissue Injury
2013 Standout
Chronic Disease in the Childhood Cancer Survivor Study Cohort: A Review of Published Findings
2009
Cancer statistics, 2023
2023 Standout
Potential of apoptotic pathway-targeted cancer therapeutic research: Where do we stand?
2016
Survival Differences between Adolescents/Young Adults and Children with B Precursor Acute Lymphoblastic Leukemia after Allogeneic Hematopoietic Cell Transplantation
2012
Mechanisms of Anthracycline Cardiac Injury: Can We Identify Strategies for Cardioprotection?
2010
Cancer treatment and survivorship statistics, 2022
2022 Standout
Cancer Statistics, 2021
2021 Standout
Cardiac complications in childhood cancer survivors treated with anthracyclines
2015
Chemotherapy resistance in osteosarcoma: current challenges and future directions
2006
Cardiac side-effects of cancer chemotherapy
2010
Doxorubicin-induced cardiomyopathy: From molecular mechanisms to therapeutic strategies
2012 Standout
Pharmacological inhibition of fatty-acid oxidation synergistically enhances the effect of l-asparaginase in childhood ALL cells
2015
Acute lymphoblastic leukaemia
2008
Anthracycline-induced cardiotoxicity: course, pathophysiology, prevention and management
2007
Current management and challenges of malignant disease in the CNS in paediatric leukaemia
2008
Cancer nanotechnology: The impact of passive and active targeting in the era of modern cancer biology
2013 Standout
Sequelae of osteosarcoma medical therapy: a review of rare acute toxicities and late effects
2010
Cardioncology: State of the heart
2013
Long-term survivors of childhood cancers: what knowledge have we gained?
2004
Biodegradable luminescent porous silicon nanoparticles for in vivo applications
2009 Standout
Anthracyclines: Molecular Advances and Pharmacologic Developments in Antitumor Activity and Cardiotoxicity
2004 Standout
Modulation of oxidative stress as an anticancer strategy
2013 Standout
Prevention of anthracycline-induced cardiotoxicity in children: The evidence
2007
Alteration of Matrix Metalloproteinases in Selective Left Ventricular Adriamycin-Induced Cardiomyopathy in the Pig
2009
Biomarker Approach to the Detection and Cardioprotective Strategies During Anthracycline Chemotherapy
2011
Doxorubicin Cardiomyopathy
2009
Survivors of childhood and adolescent cancer: life-long risks and responsibilities
2013 Standout
Multicenter randomized phase III study of the cardioprotective effect of dexrazoxane (Cardioxane®) in advanced/metastatic breast cancer patients treated with anthracycline-based chemotherapy
2006
Diffuse intrinsic pontine glioma: poised for progress
2012
The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary
2016 Standout
Molecular subgroups of medulloblastoma: the current consensus
2011
Appraising cardiotoxicity associated with liposomal doxorubicin by means of tissue Doppler echocardiography end-points
2008
Acute leukemia as a secondary malignancy in children and adolescents: Current findings and issues
2008
Osteosarcoma treatment – Where do we stand? A state of the art review
2013 Standout
Protecting against anthracycline‐induced myocardial damage: a review of the most promising strategies
2005
COMPARISON OF DOXORUBICIN CARDIOTOXICITY IN PEDIATRIC SARCOMA PATIENTS WHEN GIVEN WITH DEXRAZOXANE VERSUS AS CONTINUOUS INFUSION
2010
From Krebs to clinic: glutamine metabolism to cancer therapy
2016 Standout
Preventing or reducing late side effects of radiation therapy: radiobiology meets molecular pathology
2006 Standout
Anchor extension: a structure-guided approach to design cyclic peptides targeting enzyme active sites
2021 StandoutNobel
Chronic Health Conditions in Adult Survivors of Childhood Cancer
2006 Standout
Targeting apoptosis in cancer therapy
2020 Standout
Treatment of Acute Lymphoblastic Leukemia
2006
Light‐Controlled Histone Deacetylase (HDAC) Inhibitors: Towards Photopharmacological Chemotherapy
2015 StandoutNobel
Anthracycline associated cardiotoxicity in survivors of childhood cancer
2008
Cardiovascular Risk Reduction in High-Risk Pediatric Patients
2006
Monitoring chemotherapy-induced cardiotoxicity: Role of cardiac nuclear imaging
2006
Potentiation of Doxorubicin Cardiotoxicity by Iron Loading in a Rodent Model
2007
The Emerging Hallmarks of Cancer Metabolism
2016 Standout
Doxil® — The first FDA-approved nano-drug: Lessons learned
2012 Standout
Exercise Guidelines for Cancer Survivors: Consensus Statement from International Multidisciplinary Roundtable
2019 Standout
Targeting DNA topoisomerase II in cancer chemotherapy
2009 Standout
Pediatric posttransplant relapsed/refractory B-precursor acute lymphoblastic leukemia shows durable remission by therapy with the T-cell engaging bispecific antibody blinatumomab
2014
Prevention of Anthracycline-Induced Cardiotoxicity
2014
Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia
2014 Standout
A decade of exploring the cancer epigenome — biological and translational implications
2011 Standout
T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial
2014 Standout
Optimal therapy for acute lymphoblastic leukemia in adolescents and young adults
2011
Mechanisms of Anthracycline Cardiotoxicity and Strategies to Decrease Cardiac Damage
2010
Diagnosis, Treatment, and Long-Term Management of Kawasaki Disease: A Scientific Statement for Health Professionals From the American Heart Association
2017 Standout
PHD3 Loss in Cancer Enables Metabolic Reliance on Fatty Acid Oxidation via Deactivation of ACC2
2016 StandoutNobel
Preservation of Fertility in Patients with Cancer
2009 Standout
Recommendations for cardiomyopathy surveillance for survivors of childhood cancer: a report from the International Late Effects of Childhood Cancer Guideline Harmonization Group
2015
L‐asparaginase treatment in acute lymphoblastic leukemia
2010
Mechanisms and management of doxorubicin cardiotoxicity
2011
Immunogenic cell death and DAMPs in cancer therapy
2012 Standout
Anthracyclines suppress pheochromocytoma cell characteristics, including metastasis, through inhibition of the hypoxia signaling pathway
2017 StandoutNobel
Promoter hypermethylation in MLL-r infant acute lymphoblastic leukemia: biology and therapeutic targeting
2010
Biology, Risk Stratification, and Therapy of Pediatric Acute Leukemias: An Update
2011
Prevention of High-Dose Chemotherapy–Induced Cardiotoxicity in High-Risk Patients by Angiotensin-Converting Enzyme Inhibition
2006 Standout
Childhood and adolescent cancer statistics, 2014
2014 Standout
The 2021 WHO Classification of Tumors of the Central Nervous System: a summary
2021 Standout
DNA Topoisomerase I Inhibitors: Chemistry, Biology, and Interfacial Inhibition
2009 Standout
Leptospirosis
2001 Standout
The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes
2009 Standout
Role of Genetic Susceptibility in Development of Treatment-Related Adverse Outcomes in Cancer Survivors
2011
Nanotechnology for Multimodal Synergistic Cancer Therapy
2017 Standout
Histone Deacetylase Inhibitors in Clinical Studies as Templates for New Anticancer Agents
2015
Cardioprotective interventions for cancer patients receiving anthracyclines
2011
Late cardiotoxicity after treatment for Hodgkin lymphoma
2006
Cancer treatment and survivorship statistics, 2016
2016 Standout
Cardiotoxicity of anticancer treatments: Epidemiology, detection, and management
2016
Cardiotoxicity of Cancer Therapy
2005
Cancer treatment and survivorship statistics, 2019
2019 Standout
Ferroptosis as a target for protection against cardiomyopathy
2019 Standout
Incidence and risk-factors of CHOP/R-CHOP-related cardiotoxicity in patients with aggressive non-Hodgkin's lymphoma
2014
Long-term Cardiovascular Toxicity in Children, Adolescents, and Young Adults Who Receive Cancer Therapy: Pathophysiology, Course, Monitoring, Management, Prevention, and Research Directions
2013
Reactive Oxygen Species (ROS)-Based Nanomedicine
2019 Standout
HDACs and HDAC Inhibitors in Cancer Development and Therapy
2016
Cardiotoxicity of doxorubicin is mediated through mitochondrial iron accumulation
2014
Chronic Progressive Cardiac Dysfunction Years After Doxorubicin Therapy for Childhood Acute Lymphoblastic Leukemia
2005
Erratum: Cardiotoxicity of anticancer treatments
2015
Early Detection of Anthracycline Cardiotoxicity and Improvement With Heart Failure Therapy
2015 Standout
Diagnostic studies of the fetus, placenta and maternal blood from 265 bovine abortions.
1984
Drug‐Loaded Mesoporous Tantalum Oxide Nanoparticles for Enhanced Synergetic Chemoradiotherapy with Reduced Systemic Toxicity
2016
Monitoring for Cardiovascular Disease in Survivors of Childhood Cancer: Report From the Cardiovascular Disease Task Force of the Children's Oncology Group
2008
Doxorubicin: an update on anticancer molecular action, toxicity and novel drug delivery systems
2012 Standout
Structural Basis of Type II Topoisomerase Inhibition by the Anticancer Drug Etoposide
2011 StandoutScience
Cardiac toxicity in cancer survivors
2013
Early cardiac outcomes following contemporary treatment for childhood acute myeloid leukemia: A north American perspective
2013
American Society of Clinical Oncology Clinical Evidence Review on the Ongoing Care of Adult Cancer Survivors: Cardiac and Pulmonary Late Effects
2007
Cancer treatment and survivorship statistics, 2014
2014 Standout
Works of Yvan Samson being referenced
The Effect of Dexrazoxane on Myocardial Injury in Doxorubicin-Treated Children with Acute Lymphoblastic Leukemia
2004
Medulloblastoma in the second decade of life: A specific group with respect to toxicity and management
2005
Distinctive clinical course and pattern of relapse in adolescents with medulloblastoma
2005
A multi-centre Canadian pilot study of metronomic temozolomide combined with radiotherapy for newly diagnosed paediatric brainstem glioma
2010
Assessment of dexrazoxane as a cardioprotectant in doxorubicin-treated children with high-risk acute lymphoblastic leukaemia: long-term follow-up of a prospective, randomised, multicentre trial
2010
Doxorubicin Administration by Continuous Infusion Is Not Cardioprotective: The Dana-Farber 91-01 Acute Lymphoblastic Leukemia Protocol
2002
Height and Weight in Children Treated for Acute Lymphoblastic Leukemia: Relationship to CNS Treatment
2003
Results of the Dana-Farber Cancer Institute ALL Consortium Protocol 95-01 for children with acute lymphoblastic leukemia
2006
Favorable Outcome for Adolescents With Acute Lymphoblastic Leukemia Treated on Dana-Farber Cancer Institute Acute Lymphoblastic Leukemia Consortium Protocols
2007
Absence of Secondary Malignant Neoplasms in Children With High-Risk Acute Lymphoblastic Leukemia Treated With Dexrazoxane
2008
A phase I study of histone deacetylase inhibitor, pracinostat (SB939), in pediatric patients with refractory solid tumors: IND203 a trial of the NCIC IND program/C17 pediatric phase I consortium
2013